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ABSTRACT
In South American countries, the class A extended-spectrum b-lactamases (ESBLs) so far recognised
belong to the CTX-M, Pseudomonas Extended Resistance (PER), SHV and TEM families. ESBL rates in
South America are among the highest in the world, probably due to multiple factors. SHV- and TEM-
type ESBLs have been frequently encountered, but CTX-M is endemic and widely dominant. PER-type
ESBLs seem to be restricted to the southern ‘cone’ of South America. Community-acquired ESBLs are
starting to appear.
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EPIDEMIOLOGICAL AND
GEOGRAPHICAL DISTRIBUTION
OF EXTENDED-SPECTRUM
b -LACTAMASES
The ﬁrst reports of extended-spectrum b-lactamase
(ESBL) enzymes came from Germany in 1985 [1,2],
describing the discovery of SHV variants, specif-
ically SHV-2. By 1986–1987, Klebsiella isolates with
transmissible resistance to cefotaxime and other
b-lactams had emerged also in France [3] and, soon
after that, there was an explosion of reports of
ESBLs throughout the world. South America was
not the exception, and it has been proposed that
ESBLs, including CTX-M types, were common in
South America as early as 1989 [4].
In general, the spread of infections due to ESBL
producers has been greater in countries with
lower economic resources. This is very clear when
comparing prevalence data from Sweden (3%)
with those from Greece, Turkey, Portugal (>25%)
[5,6] or South America (>30%) [7–9]. Several
reasons may account for this disparity: (i) poorer
social and economic conditions; (ii) crowded
hospitals, frequently with high patient ⁄
nurse ratios; (iii) self-prescription of antibiotics,
which are sold over the counter in most of South
America; and (iv) deﬁcient hospital hygiene,
resulting in high rates of colonisation and infec-
tion with Klebsiella spp. This last factor is very
important because Klebsiella spp. have a particular
ability to acquire plasmids determining ESBL
production.
Based on recent multi-continent surveys, Kleb-
siella isolates from Latin America have the highest
ESBL prevalence in the world (45.4–51.9%)
[10,11]. The prevalence among Escherichia coli
isolates, ranging from 8.5% to 18.1% in Latin
American countries, was also higher than in
developed countries [11]. However, ESBL rates
among Proteus mirabilis isolates differ widely in
different continents. They were lower in northern
South America while very frequent in South
America as in Argentina (33% to 40%) [8,10,24]
(6.2%) than in eastern and southern Europe
(21.3% and 20.5%, respectively) [11].
Differences among South American countries
are observed too, although analysis is compli-
cated, depending on the isolates selected for each
study. Klebsiella isolates from intensive care units
in Brazil, Colombia and Venezuela had ESBL rates
ranging from 30% to 60% [12–18], while 56.6% of
Klebsiella pneumoniae isolates from blood samples
in Brazil were ESBL producers [19]. Among
Escherichia coli blood isolates from Uruguay and
Chile, ESBLs were expressed in 4.5% and 12%,
respectively. In Colombia, our studies of isolates
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from multiple sources showed higher rates of
ESBLs—up to 16.7%—and revealed a few clonally
related producers [20]. The absence of clonality in
most cases suggests that improved infection con-
trol will not be an adequate control measure by
itself; better antibiotic use will also be required.
TEM-type ESBLs
Most TEM-derived ESBLs, derived from TEM-1,
an extremely common enzyme known since 1965
[21,22], are more active against ceftazidime than
cefotaxime or ceftriaxone. The ﬁrst report of a
TEM-type enzyme in South America was made by
Paterson et al. in 2003, when they discovered a
TEM-10 enzyme in bloodstream isolates of
K. pneumoniae from Argentina [23]. TEM-10 and
TEM-26 are among the most common TEM ESBLs
in the USA and many European countries [20],
and Jacoby and Mun˜oz-Price recently stated that
they are also frequent in South America. How-
ever, there are marked geographical differences.
In Colombia, TEM (and SHV) ESBLs are widely
prevalent among E. coli and actually seldom
found [21] in southern South America [24].
SHV-type ESBLs
SHV-type ESBLs are all derived from SHV-1 by
point mutations, with more than 90 ESBL variants
so far described (http://www.lahey.org/studies/).
This family of ESBLs currently predominates in
surveys of resistant isolates in South America
[21,25–27]. The ﬁrst reports of SHV-type enzymes
in South America came from Argentina and Chile
in 1988 and 1989, and concern SHV-2 and SHV-5
[21]. A K. pneumoniae isolate collected during a
preclinical study of cefotaxime in Buenos Aires,
and kept lyophilised since 1982, proved to be a
producer of an SHV-5 enzyme when retrospec-
tively tested, which proves that ESBLs were
circulating long before they were recognised in
South America, or elsewhere (J. M. Casellas,
Abstracts of the International Congress of
Chemotherapy, Birmingham, UK, 1999). Today,
SHV-5 and SHV-12 are among the most common
members of this family [28].
CTX-M-type ESBLs
In 1990, Bauernfeind et al., from Mu¨nchen Uni-
versity, reported an E. coli clinical isolate obtained
in East Germany that produced a non-SHV, non-
TEM ESBL that hydrolysed cefotaxime but had
only trace activity against ceftazidime. The en-
zyme was designated CTX-M-1, thus creating the
‘cefotaximase family’ (CTX-M family), which now
comprises more than 60 enzymes [22,29]. These
enzymes are increasingly more prevalent than the
classic TEM- and SHV-type ESBLs [30].
Although the description of the ﬁrst CTX-M
enzymes came from Europe, South America was
the ﬁrst continent where they became prevalent
[29]. It now appears that CTX-M enzymes had
been widely distributed in South America from
1989 [4]. In that year, non-typhoidal Salmonella
strains producing the CTX-M-2 enzyme began to
spread from neonatal units, initially in La Plata
and Buenos Aires, Argentina. From there, these
enzymes spread to neighbouring South American
countries, including Paraguay, Uruguay and Bra-
zil [31]. By 1994, CTX-M-2 was being reported in
Klebsiella isolates from Paraguay and E. coli and
P. mirabilis isolates from Argentina [4]. Other
bacteria known to harbour this enzyme in South
America include Shigella sonnei, Morganella mor-
ganii, Citrobacter freundii, Serratia marcescens, Ente-
robacter aerogenes, Vibrio cholerae and Aeromonas
hydrophyla [4,21]. By 2002, CTX-M-2 was the
enzyme present in c. 75% of ESBL-producing
Enterobacteriaceae in Buenos Aires, making it
clearly the predominant ESBL in the country
[29,32]. CTX-M-31 (a variant of CTX-M-2) has also
been reported from Argentina [8].
Other CTX-M enzymes, including CTX-M-8,
CTX-M-9 and CTX-M-16, have been discovered in
Enterobacteriaceae from Brazil since 1996 [33].
In Colombia, seven K. pneumoniae isolates, col-
lected in 2004 from three hospitals, were positive
for CTX-M-1-group enzymes, and CTX-M-12 was
identiﬁed in one isolate [33]. This was the ﬁrst
report of CTX-M-12 outside of Kenya, where the
enzyme was found in an outbreak among six
newborn babies in 2001 [34]. Peru and Bolivia
have reported CTX-M-2, CTX-M-14, CTX-M-15,
CTX-M-24 and, recently, a new CTX-M variant,
CTX-M-56 [30,35].
Pseudomonas Extended Resistance-type ESBLs
Pseudomonas Extended Resistance (PER) enzymes
represent a distinct A ESBL class, presently
restricted to South America, Asia and Europe
[6,36,37]. These enzymes share low sequence
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homology (25–27%) with TEM, SHV or CTX-M
enzymes [37]. PER-type ESBLs are among the
most efﬁcient b-lactamases against broad-spec-
trum cephalosporins [36,37]. Two PER enzymes
from very different geographical areas are
known at present. PER-1 was ﬁrst detected in
Pseudomonas aeruginosa, Salmonella spp. and Aci-
netobacter spp. from Turkey [37], and PER-2 was
ﬁrst detected in an isolate of Salmonella enterica
recovered by Casellas et al. in Buenos Aires
[38,39]. Later on, PER-2 was detected in several
Enterobacteriaceae, and even in Vibrio cholerae
[40].
Unlike PER-1, PER-2 has never been reported
in P. aeruginosa. It seems to be restricted to
Argentina and bordering countries such as Chile,
Paraguay and Uruguay [4]. In Argentina, PER-2 is
the second most prevalent ESBL after CTX-M-2
[41].
Other ESBLs
Two novel non-TEM non-SHV ESBLs have
been reported from South America: the ceftazi-
dime-hydrolysing Guiana Extended-Spectrum-1,
isolated from K. pneumoniae from an infant
previously hospitalised in French Guiana [42],
and Brazil Extended-Spectrum-1 (BES), from an
S. marcescens isolate collected in Rio de Janeiro in
1997 [42]. BES-1 exhibits greater catalytic activity
against ceftazidime and aztreonam than do
CTX-M enzymes and was the ﬁrst ESBL shown
to exhibit selective resistance to tazobactam
[27,28].
A NEW CHALLENGE: ESBLs IN
COMMUNITY-ACQUIRED INFECTIONS
Most community-acquired ESBL producers in
Latin America and in other developing countries
are Salmonella and Shigella spp. isolates [43,44].
However, several reports of community-acquired
E. coli and K. pneumoniae infection not related to
nursing homes or hospitals have been published
in the past several years. These reports come from
Spain, France, Israel, the UK and Canada, and
mostly concern strains with the CTX-M-class
enzymes. In the last year, at least two or three
community-acquired infections due to ESBL
producers have been detected in Argentina
(J. M. Casellas, unpublished data). A recent report
from Brazil showed a 1.48% prevalence of ESBLs
among enterobacterial isolates collected from
urine samples in ambulatory patients between
2000 and 2002. TEM-type enzymes were identi-
ﬁed in 95.4% of the isolates, with SHV types
being found in most of the remainder, although
seven strains produced CTX-M-type enzymes.
Pulsed-ﬁeld gel electrophoresis showed several
identical genotypes, indicating a common source
of acquisition [45]. Surveys of over 3000 healthy
children from low-resource settings in Bolivia and
Peru revealed an increase in faecal carriage of
ESBL-producing E. coli from 0.1% in 2002 to 1.7%
in 2005 [30]. Of 50 ESBL-producing isolates
collected in 2005, 44 harboured a CTX-M-type
enzyme and six had SHV-type enzymes.
REFERENCES
1. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM,
Wiedemann B. Evolution of plasmid-coded resistance to
broad-spectrum cephalosporins. Antimicrob Agents Che-
mother 1985; 28: 302–307.
2. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S.
Transferable resistance to cefotaxime, cefoxitin, cefaman-
dole and cefuroxime in clinical isolates of Klebsiella pneu-
moniae and Serratia marcescens. Infection 1983; 11: 315–317.
3. Brun-Buisson C, Legrand P, Philippon A, Montravers F,
Ansquer M, Duval J. Transferable enzymatic resistance to
third-generation cephalosporins during nosocomial out-
break of multiresistant Klebsiella pneumoniae. Lancet 1987; 2:
302–306.
4. Radice M, Power P, Di Conza J, Gutkind G. Early dis-
semination of CTX-M-derived enzymes in South America.
Antimicrob Agents Chemother 2002; 46: 602–604.
5. Ilanberge JL, Garcı´a Rodriguez JA, Gobernado M, Goos-
sens JL, Nilsson LE, Struelens MJ. Antibiotic susceptibility
among aerobic gram-negative bacilli in intensive care units
in 5 European countries. French and Portuguese ICU
Study Groups. JAMA 1992; 281: 67–71.
6. Paterson DL, Bonomo RA. Extended-spectrum beta-lacta-
mases: a clinical update. Clin Microbiol Rev 2005; 18: 657–
686.
7. Casellas JM. South America: a different continent, different
ESBLs. J Antimicrob Chemother 1999; 44 (suppl A): 16.
8. Quinteros M, Radice M, Gardella N et al. Extended-spec-
trum beta-lactamases in enterobacteriaceae in Buenos
Aires, Argentina, public hospitals. Antimicrob Agents Che-
mother 2003; 47: 2864–2867.
9. Sader HS, Jones RN, Gales AC et al. The SENTRY Partic-
ipants Group (Latin America). SENTRY Antimicrobial
Surveillance Program Report: Latin American and Brazil-
ian Results for 1997 through 2001. Braz J Infect Dis 2006; 8:
25–79.
10. Winokur PL, Canton R, Casellas JM, Legakis N. Varia-
tions in the prevalence of strains expressing an ex-
tended-spectrum beta-lactamase phenotype and
characterization of isolates from Europe, the Americas,
and the Western Paciﬁc region. Clin Infect Dis 2001; 32
(suppl 2): S94–S103.
156 Clinical Microbiology and Infection, Volume 14, Supplement 1, January 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 154–158
11. Turner PJ, Greenhalgh JM, Edwards JR, McKellar J. The
MYSTIC (meropenem yearly susceptibility test informa-
tion collection) programme. Int J Antimicrob Agents 1999;
13: 117–125.
12. Mendes C, Hsiung A, Kiffer C et al. Evaluation of the
in vitro activity of 9 antimicrobials against bacterial strains
isolated from patients in intensive care units in brazil:
MYSTIC Antimicrobial Surveillance Program. Braz J Infect
Dis 2000; 4: 236–244.
13. Otman J, Cavassin ED, Perugini ME, Vidotto MC. An
outbreak of extended-spectrum beta-lactamase-producing
Klebsiella species in a neonatal intensive care unit in Brazil.
Infect Control Hosp Epidemiol 2002; 23: 8–9.
14. Pfaller MA, Jones RN, Doern GV. Multicenter evaluation
of the antimicrobial activity for six broad-spectrum beta-
lactams in Venezuela: comparison of data from 1997 and
1998 using the Etest method. Venezuelan Antimicrobial
Resistance Study Group. Diagn Microbiol Infect Dis 1999;
35: 153–158.
15. Pfaller MA, Jones RN, Doern GV, Salazar JC. Multicenter
evaluation of antimicrobial resistance to six broad-spec-
trum beta-lactams in Colombia: comparison of data from
1997 and 1998 using the Etest method. The Colombian
Antimicrobial Resistance Study Group. Diagn Microbiol
Infect Dis 1999; 35: 235–241.
16. Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN.
Prevalence of antimicrobial resistance among respiratory
tract isolates in Latin America: results from SENTRY
antimicrobial surveillance program (1997–98). Braz J Infect
Dis 2000; 4: 245–254.
17. Sader HS, Jones RN, Gales AC et al. Antimicrobial sus-
ceptibility patterns for pathogens isolated from patients in
Latin American medical centers with a diagnosis of
pneumonia: analysis of results from the SENTRY Anti-
microbial Surveillance Program (1997). SENTRY Latin
America Study Group. Diagn Microbiol Infect Dis 1998; 32:
289–301.
18. Miranda MC, Perez F, Zuluaga T et al. Resistencia a anti-
microbianos en bacilos Gram negativos aislados en unid-
ades de cuidado intensivo en hospitales de Colombia,
WHONET 2003, 2004 y 2005. Biomedica 2006; 26: 424–433.
19. Motta RN, Oliveira MM, Magalhaes PS et al. Plasmid-
mediated extended-spectrum beta-lactamase-producing
strains of Enterobacteriaceae isolated from diabetes foot
infections in a Brazilian diabetic center. Braz J Infect Dis
2003; 7: 129–134.
20. Villegas MV, Correa A, Perez F et al. Prevalence and
characterization of extended-spectrum beta-lactamases in
Klebsiella pneumoniae and Escherichia coli isolates from
Colombian hospitals. Diagn Microbiol Infect Dis 2004; 49:
217–222.
21. Paterson DL, Hujer KM, Hujer AM et al. Extended-spec-
trum beta-lactamases in Klebsiella pneumoniae bloodstream
isolates from seven countries: dominance and widespread
prevalence of SHV- and CTX-M-type beta-lactamases.
Antimicrob Agents Chemother 2003; 47: 3554–3560.
22. Govinden U, Mocktar C, Moodley P, Sturm AW, Essack
SY. Geographical evolution of the CTX-M b-lactamase—an
update. Afr J Biotechnol 2007; 6: 831–839.
23. Jacoby GA, Munoz-Price LS. The new beta-lactamases.
N Engl J Med 2005; 352: 380–391.
24. Casellas JM, Tome´ G, Bantar C et al. Argentinean collab-
orative multicenter study on the in vitro comparative
activity of piperacillin–tazobactam against selected bacte-
rial isolates recovered from hospitalized patients. Diagn
Microb Infect Dis 2003; 47: 247–257.
25. Ben RS, Ben YH, Boujnah A, Philippon A, Labia R.
Synergy between clavulanic acid and newer beta-lactams
on nine clinical isolates of Klebsiella pneumoniae, Escheri-
chia coli and Salmonella typhimurium resistant to third-
generation cephalosporins. J Antimicrob Chemother 1988;
21: 263–266.
26. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended
broad-spectrum beta-lactamases conferring transferable
resistance to newer beta-lactam agents in Enterobacteria-
ceae: hospital prevalence and susceptibility patterns. Rev
Infect Dis 1988; 10: 867–878.
27. Casellas JM, Goldberg M. Incidence of strains producing
extended spectrum beta-lactamases in Argentina. Infection
1989; 17: 434–436.
28. Bauernfeind A, Casellas JM, Goldberg M et al. A new
plasmidic cefotaximase from patients infected with Sal-
monella typhimurium. Infection 1992; 20: 158–163.
29. Bonnet R, Dutour C, Sampaio JL et al. Novel cefotaximase
(CTX-M-16) with increased catalytic efﬁciency due to
substitution Asp-240–>Gly. Antimicrob Agents Chemother
2001; 45: 2269–2275.
30. Pallecchi L, Bartoloni A, Fiorelli C et al. Rapid dissemi-
nation and diversity of CTX-M extended-spectrum beta-
lactamase genes in commensal Escherichia coli from healthy
children from low-resource settings of Latin America.
Antimicrob Agents Chemother 2007; 51: 2720–2725.
31. Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Cas-
ellas JM. Sequences of beta-lactamase genes encoding
CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their
amino acid sequences with those of other beta-lactamases.
Antimicrob Agents Chemother 1996; 40: 509–513.
32. Bonnet R, Sampaio JL, Labia R et al. A novel CTX-M beta-
lactamase (CTX-M-8) in cefotaxime-resistant Enterobacte-
riaceae isolated in Brazil. Antimicrob Agents Chemother
2000; 44: 1936–1942.
33. Villegas MV, Correa A, Perez F et al. CTX-M-12 beta-lac-
tamase in a Klebsiella pneumoniae clinical isolate in
Colombia. Antimicrob Agents Chemother 2004; 48: 629–631.
34. Kariuki S, Corkill JE, Revathi G, Musoke R, Hart CA.
Molecular characterization of a novel plasmid-encoded
cefotaximase (CTX-M-12) found in clinical Klebsiella pneu-
moniae isolates from Kenya. Antimicrob Agents Chemother
2001; 45: 2141–2143.
35. Pallecchi L, Malossi M, Mantella A et al. Detection of CTX-
M-type beta-lactamase genes in fecal Escherichia coli iso-
lates from healthy children in Bolivia and Peru. Antimicrob
Agents Chemother 2004; 48: 4556–4561.
36. Nordmann P, Naas T. Sequence analysis of PER-1 ex-
tended-spectrum beta-lactamase from Pseudomonas aeru-
ginosa and comparison with class A beta-lactamases.
Antimicrob Agents Chemother 1994; 38: 104–114.
37. Bauernfeind A, Stemplinger I, Jungwirth R et al. Charac-
terization of beta-lactamase gene blaPER-2, which encodes
an extended-spectrum class A beta-lactamase. Antimicrob
Agents Chemother 1996; 40: 616–620.
38. Rossi A, Lopardo H, Woloj M et al. Non-typhoid Salmo-
nella spp. resistant to cefotaxime. J Antimicrob Chemother
1995; 36: 697–702.
39. Petroni A, Corso A, Melano R et al. Plasmidic extended-
spectrum beta-lactamases in Vibrio cholerae O1 El Tor
Villegas et al. ESDLs in South America 157
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 154–158
isolates in Argentina. Antimicrob Agents Chemother 2002; 46:
1462–1468.
40. Rodriguez C, Radice M, Perazzi B et al. Enzymatic resis-
tance to beta lactam antibiotics within the genus Proteus
and evaluation of Proteus mirabilis phenotypes and geno-
types for resistance to third- and fourth-generation ceph-
alosporins. Enferm Infecc Microbiol Clin 2005; 23: 122–126.
41. Poirel L, Le TI, Naas T, Karim A, Nordmann P. Bio-
chemical sequence analyses of GES-1, a novel class A ex-
tended-spectrum beta-lactamase, and the class 1 integron
In52 from Klebsiella pneumoniae. Antimicrob Agents Chemo-
ther 2000; 44: 622–632.
42. Bonnet R, Sampaio JL, Chanal C et al. A novel class A
extended-spectrum beta-lactamase (BES-1) in Serratia
marcescens isolated in Brazil. Antimicrob Agents Chemother
2000; 44: 3061–3068.
43. Mirelis B, Navarro F, Miro E, Mesa RJ, Coll P, Prats G.
Community transmission of extended-spectrum beta-lac-
tamase. Emerg Infect Dis 2003; 9: 1024–1025.
44. Colodner R, Rock W, Chazan B et al. Risk factors for the
development of extended-spectrum beta-lactamase-pro-
ducing bacteria in nonhospitalized patients. Eur J Clin
Microbiol Infect Dis 2004; 23: 163–167.
45. Minarini LA, Gales AC, Palazzo IC, Darini AL. Prevalence
of community-occurring extended spectrum beta-lactam-
ase-producing Enterobacteriaceae in Brazil. Curr Microbiol
2007; 54: 335–341.
158 Clinical Microbiology and Infection, Volume 14, Supplement 1, January 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 154–158
